Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225817312> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W4225817312 endingPage "204" @default.
- W4225817312 startingPage "201" @default.
- W4225817312 abstract "This American Epilepsy Society (AES) official statement provides information and preliminary guidance to Society members related to the U.S. Food & Drug Administration (FDA) December 22, 2021 Emergency Use Authorization for Paxlovid™ for the oral treatment of mild to moderate COVID-19 in adults and children (≥12 years and weighing ≥40 kg). Paxlovid is likely to be widely prescribed, and important considerations for patients on antiseizure medications (ASMs) include key contraindications and potential toxicity or dose adjustments while taking Paxlovid. This statement highlights concerns and provides information about their pharmacologic basis. Of particular concern, concomitant use of Paxlovid with the ASMs carbamazepine, phenobarbital, phenytoin, and primidone is contraindicated, because they are strong inducers of the CYP3A4 isozyme that metabolizes Paxlovid and thereby could cause loss of virologic response and development of resistance. Alternate oral or intravenous COVID-19 treatments should be considered. A second concern is that Paxlovid may increase the plasma concentrations of many ASMs, because it inhibits the CYP3A4 isozyme. ASMs that are metabolized, at least in part, by CYP3A4 include cannabidiol, carbamazepine, clobazam, clonazepam, diazepam, ethosuximide, everolimus, felbamate, lacosamide, midazolam, oxcarbazepine, perampanel, stiripentol, tiagabine, and zonisamide. Patients receiving these medications may warrant closer monitoring while being treated with Paxlovid." @default.
- W4225817312 created "2022-05-05" @default.
- W4225817312 creator A5000233437 @default.
- W4225817312 creator A5002483148 @default.
- W4225817312 creator A5060793900 @default.
- W4225817312 creator A5082183128 @default.
- W4225817312 date "2022-04-04" @default.
- W4225817312 modified "2023-10-10" @default.
- W4225817312 title "Paxlovid<sup>TM</sup> Information From FDA and Guidance for AES Members" @default.
- W4225817312 cites W1993337516 @default.
- W4225817312 cites W2040185039 @default.
- W4225817312 cites W2125091429 @default.
- W4225817312 cites W4200206478 @default.
- W4225817312 doi "https://doi.org/10.1177/15357597221088415" @default.
- W4225817312 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36451851" @default.
- W4225817312 hasPublicationYear "2022" @default.
- W4225817312 type Work @default.
- W4225817312 citedByCount "6" @default.
- W4225817312 countsByYear W42258173122023 @default.
- W4225817312 crossrefType "journal-article" @default.
- W4225817312 hasAuthorship W4225817312A5000233437 @default.
- W4225817312 hasAuthorship W4225817312A5002483148 @default.
- W4225817312 hasAuthorship W4225817312A5060793900 @default.
- W4225817312 hasAuthorship W4225817312A5082183128 @default.
- W4225817312 hasBestOaLocation W42258173121 @default.
- W4225817312 hasConcept C118552586 @default.
- W4225817312 hasConcept C177713679 @default.
- W4225817312 hasConcept C2776749334 @default.
- W4225817312 hasConcept C2777332695 @default.
- W4225817312 hasConcept C2777907850 @default.
- W4225817312 hasConcept C2777992146 @default.
- W4225817312 hasConcept C2778139780 @default.
- W4225817312 hasConcept C2778186239 @default.
- W4225817312 hasConcept C2779253243 @default.
- W4225817312 hasConcept C2779426884 @default.
- W4225817312 hasConcept C2781011581 @default.
- W4225817312 hasConcept C2781176495 @default.
- W4225817312 hasConcept C42219234 @default.
- W4225817312 hasConcept C71924100 @default.
- W4225817312 hasConcept C98274493 @default.
- W4225817312 hasConceptScore W4225817312C118552586 @default.
- W4225817312 hasConceptScore W4225817312C177713679 @default.
- W4225817312 hasConceptScore W4225817312C2776749334 @default.
- W4225817312 hasConceptScore W4225817312C2777332695 @default.
- W4225817312 hasConceptScore W4225817312C2777907850 @default.
- W4225817312 hasConceptScore W4225817312C2777992146 @default.
- W4225817312 hasConceptScore W4225817312C2778139780 @default.
- W4225817312 hasConceptScore W4225817312C2778186239 @default.
- W4225817312 hasConceptScore W4225817312C2779253243 @default.
- W4225817312 hasConceptScore W4225817312C2779426884 @default.
- W4225817312 hasConceptScore W4225817312C2781011581 @default.
- W4225817312 hasConceptScore W4225817312C2781176495 @default.
- W4225817312 hasConceptScore W4225817312C42219234 @default.
- W4225817312 hasConceptScore W4225817312C71924100 @default.
- W4225817312 hasConceptScore W4225817312C98274493 @default.
- W4225817312 hasIssue "3" @default.
- W4225817312 hasLocation W42258173121 @default.
- W4225817312 hasLocation W42258173122 @default.
- W4225817312 hasLocation W42258173123 @default.
- W4225817312 hasOpenAccess W4225817312 @default.
- W4225817312 hasPrimaryLocation W42258173121 @default.
- W4225817312 hasRelatedWork W1494361836 @default.
- W4225817312 hasRelatedWork W1998249177 @default.
- W4225817312 hasRelatedWork W2054250310 @default.
- W4225817312 hasRelatedWork W2132687986 @default.
- W4225817312 hasRelatedWork W2147863158 @default.
- W4225817312 hasRelatedWork W2328803946 @default.
- W4225817312 hasRelatedWork W2503698847 @default.
- W4225817312 hasRelatedWork W4205673303 @default.
- W4225817312 hasRelatedWork W4312284432 @default.
- W4225817312 hasRelatedWork W1876911850 @default.
- W4225817312 hasVolume "22" @default.
- W4225817312 isParatext "false" @default.
- W4225817312 isRetracted "false" @default.
- W4225817312 workType "article" @default.